


Expanded View Figures

Figure EV1. Tolerance of bronchial epithelial cells to metabolite exposure.

(A) BEAS-2B cells were treated with medium alone or with 3.4 mM *cis*-aco (CA), itaconate (Ita), oxaloacetate (Oxa), isocitrate (IsoC), citrate (Cit), fumarate (Fum), pyruvate (Pyr) or glucose (Glc) for 16 h. Cytotoxicity was assessed using the MTS assay. (B–E) BEAS-2B cells were treated (blue) or not (white) with 1.2 or 2.3 or 3.4 mM *cis*-aco for 20 h (B) or with 3.4 mM *cis*-aco for 6 or 24 h (C–E). Effects on cell viability (B), proliferation (C), mitochondrial labeling (D), and ROS production (E) were analyzed using Live Dead, Ki67, mitotracker and DHR123 staining, respectively. (F, G) PBEC were treated with 2.3, 3.4 or 5.7 mM *cis*-aco for 16 h, and cytotoxicity was assessed using the MTS assay and propidium iodide labeling. (H) PBEC in air-liquid interface (ALI) were treated with 5.7 mM *cis*-aco for 44 h, and cytotoxicity was assessed using the MTS assay. Data are presented as the mean $\pm$ SEM from 4 (B–F) or 5 (A) independent experiments. The number of data points shown in each bar plot corresponds to the number of independent experiments performed for that condition. Statistical analyses were performed using the Kruskal–Wallis test with Dunn's multiple comparison test (A, B, F), the Friedman test with Dunn's multiple comparison test (C–E) or the Wilcoxon matched-pairs signed rank test (G, H). Statistical significance: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.






Figure EV2. Comparison of anti-influenza effects of *cis*-aco and *trans*-aco.

BEAS-2B cells were incubated with medium alone or with increasing concentrations of *cis*-aconitic (CA) or *trans*-aconitic acid (TA) for 20 h. The chemical structures of these metabolites are shown in (A). (B) Cell viability was assessed using the MTS assay. A viability threshold of 80% was set (red dashed line). (C, D) BEAS-2B cells were infected with influenza A/Scotland/20/74 (H3N2) virus (IAV) at an MOI = 1 (pink bars) or left uninfected (NI) for 4 h, followed by treatment or not with increasing concentrations of CA (blue) or TA (green) for 16 h. (C) Viral particle production was assessed using a neuraminidase activity assay. (D) IL-6 levels in cell supernatants were measured by ELISA. Data are presented as the mean ± SEM and represent cumulative results from 4 or 5 independent experiments. The number of data points shown in each bar plot corresponds to the number of independent experiments performed for that condition. Statistical analysis was performed using the Kruskal-Wallis test with Dunn's multiple comparison test. Statistical significance: **P* < 0.05, ***P* < 0.01, ****P* < 0.001, *****P* < 0.0001.




Figure EV3. Cis-aco protects against IAV-induced cell death in human primary bronchial epithelial cells (PBEC).

(A, B) PBEC were infected with virus A/Scotland/20/74 (H3N2) at an MOI = 1, and treated or not with 3.4 mM *cis*-aco (CA) 10 min p.i. SYTOXTM labeling was monitored over 18 h. Representative images ((A); scale bar: 200 μ m) and quantification of labeling (B) at 18 h p.i. were used to assess cell death. Data are presented as the mean $\pm$ SEM from duplicate PBEC derived from 4 independent patients analyzed. The number of data points shown in each bar plot corresponds to the number of independent experiments performed for that condition. Statistical analysis was performed using the Friedman test with Dunn's multiple comparison test. Statistical significance: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.




Figure EV4. Tolerance and safety of *cis*-aco in vivo.

Seven-week-old female and male C57Bl/6 mice were intranasally instilled with PBS or 30 mg/kg *cis*-aco (CA) for 15 days, according to the schedule outlined. (A) Body weight was monitored throughout the study. (B) Mice were euthanized on day 15 and serum was collected to determine ALAT activity levels. (C) Microbiota alterations were assessed in mouse fecal pellets, after genomic DNA extraction and 16S rRNA sequencing. Microbial community diversity was quantified using Aitchison distance values, a measure of beta diversity. Each point represents the Aitchison distance between a CA-treated mouse and a PBS-treated mouse at day 0, 7, or 14. (D) The number of immune cells in BAL fluids was assessed by flow cytometry. (E) Blood cell analysis was also conducted. Data from (E) represent pooled results from 3 mice. All other data are presented as the mean $\pm$ SEM and are cumulative (A–C) or representative (D) of 3 independent experiments. The number of data points shown in each bar plot corresponds to the number of independent experiments performed for that condition. Statistical analysis was performed using the Mann-Whitney test (B, D) or the Kruskal-Wallis test with Dunn's multiple comparison test. Statistical significance: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.




Figure EV5. Confirmation of the protective effects of cis-aco in IAV-infected Balb/c mice.

To validate the findings observed in C57Bl/6 mice (see Fig. 3A–D) in a different mouse strain and sex, we conducted an experiment using male Balb/c mice. These (NF- κ B transgenic) Balb/c animals were infected with 300 PFU of A/Scotland/20/74 (H3N2) IAV and treated intranasally with 30 mg/kg *cis*-aco (CA) 2 days p.i. Survival (A) and body weight (B) were monitored daily. All data are presented as the mean $\pm$ SEM. Statistical analysis was performed using the Log-rank (Mantel-Cox) test. Statistical significance: * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.